Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02906332
Title Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hackensack University Medical Center
Indications

multiple myeloma

Therapies

Pembrolizumab

Dexamethasone

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.